drugset / Trial / NCT06110403

Impact of Long-acting Bronchodilator- -Corticoid Inhaled Therapy on Ventilation, Lung Function and Breathlessness

NCT06110403

Phase 1/2 Recruiting 35 enrolled University Hospital, Lille AstraZeneca · collab
NaSingle-groupOpen-labelTreatment

Summary

Multicentre, prospective, non-randomised, single-arm, open label, mechanistic study to investigate the mechanism of action of BGF 160 on ventilation pattern complexity and variability

Timeline

Start
2023-09-29
Primary completion
2026-09
Completion
2026-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Budesonide Small molecule 160 ug Inhaled
Subject Formoterol Other / unclassified 4.8 ug Inhaled
Subject Glycopyrrolate Small molecule 9 ug Inhaled